AAV Stability & Titer In Viral Vector Manufacturing

With Fluorescence Membrane Microscopy, getting to the root of AAV stability issues is quick and easy. Our innovative technology only requires 5 µL of material for ultra-fast insights, so you can gain clarity into gene therapy formulations sooner.

Characterize AAV Stability in Late Discovery

shutterstock_1892875636 (1)@2x

Why Use Aura to Monitor DNA Leakage-Based SVP Aggregation?

Because you can achieve so much more insight with much less material:
  • Achieve more accurate results with minimal amounts of sample (as little as 5 μL per test)
  • ID SYBR-labeled DNA aggregates from unstable AAV vectors
  • Detect and quantitate particles not measured by DLS or SEC
  • Determine root cause for unstable gene therapies
  • 96-well format for high-throughput testing
  • Gather comprehensive data and insight into aggregate particles – size, morphology, counts, distribution
  • Get insights quickly with rapid analysis time of 1 minute per sample
  • Benefit from a wide working range: measure particles from 1 μm to 5 mm with high reproducibility
  • Analyze particles without the interference of buffer or matrix for higher sensitivity
  • 21 CFR Part 11 software available

Identify Root Cause of Aggregates at Low Volume

Detect DNA leakage from stressed AAV empty or full capsids and to determine the cause of AAV aggregation.

FMM Empowers High-Throughput Subvisible Particle Characterization

Scatterplot data for (a) full AAV capsids and (b) empty AAV capsids. The y-axis represents fluorescence intensity in the SYBR Gold channel, and the x-axis represents the equivalent circular diameter (ECD) for the individual particle. The full AAV capsid (left) had 16–fold as many particles and almost 3x stronger average fluorescence intensity than the empty capsid sample (right).

Frequently Asked Questions

Increasing AAV (Adeno-associated virus) production involves optimizing various steps in the manufacturing process to enhance vector yield and efficiency. Strategies for increasing AAV production include:

  • Cell Culture Optimization: Creating and maintaining cell culture conditions, such as media composition, cell density, and bioreactor parameters, to maximize AAV production.
  • Transfection Efficiency: Improving transfection efficiency by optimizing transfection protocols, using transfection enhancers, or employing novel transfection methods.
  • Vector Design: Engineering AAV vectors with enhanced transduction efficiency and stability to increase vector yield.
  • Purification Optimization: Streamlining purification processes to improve AAV recovery and purity while reducing processing time and costs.
  • Process Scale-Up: Scaling up production processes using larger bioreactors or high-density cell culture systems to increase AAV production capacity.
  • Technology Innovation: Implementing advanced manufacturing technologies, such as single-use bioreactors, continuous processing, and automation, to improve efficiency and scalability.

By implementing these strategies and technologies, researchers and manufacturers can enhance AAV production capabilities to meet the growing demand for gene therapy applications.